566 Appendices 164. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. The New England journal of medicine. 2012;367:705-715. https://doi. org/10.1056/NEJMoa1203208. 165. Alexander EK, Schorr M, Klopper J, Kim C, Sipos J, Nabhan F, et al. Multicenter clinical experience with the Afirma gene expression classifier. The Journal of clinical endocrinology and metabolism. 2014;99:119-125. https://doi. org/10.1210/jc.2013-2482. 166. Duick DS, Klopper JP, Diggans JC, Friedman L, Kennedy GC, Lanman RB, et al. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid. 2012;22:996-1001. https://doi.org/10.1089/ thy.2012.0180. 167. Witt RL. Outcome of thyroid gene expression classifier testing in clinical practice. The Laryngoscope. 2016;126:524527. https://doi.org/10.1002/lary.25607. 168. McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. The Journal of clinical endocrinology and metabolism. 2014;99:4069-4077. https://doi.org/10.1210/jc.2013-3584. 169. Yang SE, Sullivan PS, Zhang J, Govind R, Levin MR, Rao JY, et al. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology? Cancer cytopathology. 2016;124:100-109. https://doi.org/10.1002/cncy.21624. 170. Brauner E, Holmes BJ, Krane JF, Nishino M, Zurakowski D, Hennessey JV, et al. Performance of the Afirma Gene Expression Classifier in Hurthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules. Thyroid. 2015;25:789-796. https://doi.org/10.1089/thy.2015.0049. 171. Celik B, Whetsell CR, Nassar A. Afirma GEC and thyroid lesions: An institutional experience. Diagnostic cytopathology. 2015;43:966-970. https://doi.org/10.1002/dc.23378. 172. Marti JL, Avadhani V, Donatelli LA, Niyogi S, Wang B, Wong RJ, et al. Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules. Annals of surgical oncology. 2015. https://doi. org/10.1245/s10434-015-4486-3. 173. Noureldine SI, Olson MT, Agrawal N, Prescott JD, Zeiger MA, Tufano RP. Effect of Gene Expression Classifier Molecular Testing on the Surgical Decision-Making Process for Patients With Thyroid Nodules. JAMA otolaryngology - head & neck surgery. 2015;141:1082-1088. https://doi.org/10.1001/jamaoto.2015.2708. 174. Aragon Han P, Olson MT, Fazeli R, Prescott JD, Pai SI, Schneider EB, et al. The impact of molecular testing on the surgical management of patients with thyroid nodules. Annals of surgical oncology. 2014;21:1862-1869. https://doi. org/10.1245/s10434-014-3508-x. 175. Wu JX, Lam R, Levin M, Rao J, Sullivan PS, Yeh MW. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules. Surgery. 2016;159:118-129. https://doi.org/10.1016/j. surg.2015.05.035. 176. Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. The Journal of clinical endocrinology and metabolism. 2011;96:E1719-1726. https:// doi.org/10.1210/jc.2011-0459. 177. Heinzel A, Muller D, Behrendt FF, Giovanella L, Mottaghy FM, Verburg FA. Thyroid nodules with indeterminate cytology: molecular imaging with (9)(9)mTc-methoxyisobutylisonitrile (MIBI) is more cost-effective than the Afirma gene expression classifier. Eur J Nucl Med Mol Imaging. 2014;41:1497-1500. https://doi.org/10.1007/s00259-014-2760-4. 178. Labourier E. Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology. Clinical endocrinology. 2016;85:624-631. https://doi.org/10.1111/cen.13096. 179. Macias AA, Eappen S, Malikin I, Goldfarb J, Kujawa S, Konowitz PM, et al. Successful intraoperative electrophysiologic monitoring of the recurrent laryngeal nerve, a multidisciplinary approach: The Massachusetts Eye and Ear Infirmary monitoring collaborative protocol with experience in over 3000 cases. Head & neck. 2016;38:1487-1494. https://doi. org/10.1002/hed.24468. 180. Harrell RM, Bimston DN. Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology. Endocrine practice. 2014;20:364-369. https://doi.org/10.4158/ep13330.or. 181. Santhanam P, Khthir R, Gress T, Elkadry A, Olajide O, Yaqub A, et al. Gene expression classifier for the diagnosis of indeterminate thyroid nodules: a meta-analysis. Medical oncology. 2016;33:14. https://doi.org/10.1007/s12032-015-0727-3. 182. Lastra RR, Pramick MR, Crammer CJ, LiVolsi VA, Baloch ZW. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience. Cancer cytopathology. 2014;122:737-744. https://doi. org/10.1002/cncy.21455. 183. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2005;102:19075-19080. https://doi.org/10.1073/pnas.0509603102. 184. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-related cancer. 2006;13:497-508. https://doi.org/10.1677/erc.1.01209.
RkJQdWJsaXNoZXIy MTk4NDMw